Pemivibart

Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19.^[4] Pemivibart was developed by Invivyd.^[3][5]

Pemivibart

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Spike protein of SARS-CoV-2
Clinical data
Trade names	Pemgarda
Other names	VYD222
AHFS/Drugs.com	Monograph
MedlinePlus	a624061
License data	US DailyMed: Pemivibart
Routes of administration	Intravenous
ATC code	None
Legal status
Legal status	US: ℞-only via EUA[1][2][3]
Identifiers
CAS Number	2858673-18-2
DrugBank	DB18720
UNII	557S3L3FAP
KEGG	D12876

The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.^[4][5]

Medical uses

In the US, pemivibart is authorized for the pre-exposure prophylaxis (prevention) of COVID‑19 in people aged twelve years or older weighing at least 40 kilograms (88 lb).^[4] Pemivibart is authorized for individuals who are not currently infected with SARS-CoV-2—the virus that causes COVID-19—and have not been recently exposed to the virus. It is intended for individuals with moderate to severe immunocompromise due to a medical condition or immunosuppressive treatment, as they are less likely to respond effectively to SARS-CoV-2 vaccination.^[4]

In August 2024, the US Food and Drug Administration (FDA) revised the emergency use authorization for pemivibart to limit its use to when the combined national frequency of variants with substantially reduced susceptibility to pemivibart is less than or equal to 90%.^[2][3][6][7]

Society and culture

Legal status

The US FDA issued an emergency use authorization for pemivibart in March 2024.^[4][7][8]

Names

Pemivibart is the international nonproprietary name.^[9]